call for this afternoon. Well, the thanks Erik the in the for thanks participants comments,
pipeline specifically programs, clinical As updates which some moving well. all our Kevin on mentioned, along provide five are I’ll
So two programs. with the let's start valbenazine
about long-term that psychiatric commercial and we accepted steady of The team three We and publication neurology. tardive psychiatry of at dyskinesia, College later patient pleased manuscripts and connect extension multiple the the Erik, year up flow including been engagement leaders scientific submitted has with clinical just scientific been sharing a importance. American data upcoming are INGREZZA been stability First very anticipate medical do has from with XXXX. up other more also successful topics of of launch both coming data, group aspects affairs of and is meetings with specific data has in the having which subtype planned heard Psycho-Neuropsychopharmacology this the for analyses, you recently medical our affairs in the including
valbenazine a sufficient in important modeling with study, data design our up GOLD response set to were screen. to is currently that T-Force with granted screen For that of T-Force up study, the from FDA that wrapping data And clinical which with open followed we're us the study. orphan designation patients the the exposure some got study, T-Force we busy we've The Syndrome, very for T-Force is fusion study extension with pleased that label very conjunction was Tourettes. for fusion Tourette recently which pediatric disease team come because able
held couple which the GOLD patients. T-Force investigator was pediatric is meeting, now study following in So October, just weeks the enrolling a ago,
and placebo last optimization in new randomization controlled dose see will it placebo. trial our The that II and controlled the six valbenazine placebo controlled a T-Force You period subjects, rate kids being conducted the years And complete data offer late prior patients beginning trial The our for trial, release also noted Tourette trials, of States. about in we XXX these eighteen twelve this other study. this that the is is on from approximately randomize is clinicaltrials.gov. those it syndrome higher patients of so design week, portion. the doses trial a who excited open one with We study anticipate press of can and blind enroll. of as the includes will double treatment weeks one to age. used Phase top-line that aged for extension as includes all randomized are obviously an and in strategy trial United through recruitment in Like were the label GOLD that's for on dependent to huge progress XXXX, those very on trial The
Turning molecule NBI-XXXXX the Phase II Adrenal about with to clinical call that This begin. study is Hyperplasia. to Congenital we
top-line we expect initiating and in the as are sites of data speak We we first XXXX. half
descriptions, CAH. will the that study follow. a to then that If is we pediatric with you request confirm to study FDA based patients on the With we with hope recall data in this adult in for meeting goal hand, with details prior discuss trial design our proof-of-concept will
– the treatment turning with of plans designed were now readout Parkinson's submission in keep for half January this our the opicapone meeting XXXX of the first requested of So the to and in meeting NDA granted disease. disease, XXXX have And to program the we the for early for of opicapone is confirm a FDA Parkinson's and you updated. data will in we and
month to approximately FDA would provide As then meeting face minutes the usual meetings, with meeting. formal face after these the one
that. So we'll keep updated on you
with As quality has in to of a beginning Kevin progress have range high publications. mentioned, but made across happy are partners scientific job generating not share data, really They elagolix AbbVie. tremendous and we by meetings now been a the with data that that only our done
they’re recently, of data into treatment. about The long-term won't Journal out So England through of rolling pivotal months and Medicine efficacy really the out after twelve And now all go publication additional details in New the safety the I abstracts.
You requiring benefit of one, from going let this to pain you take when the With in persistence XX both pelvic XX% I patients at these of has data. to the a look remarkable difficult the read a sorry remarkable opiates week, aggressive is key rate rate of responder to Medicine responder I on yourself with and see point of for that menstrual in American Society pain. – syndrome taken and away dysmenorrhea is often that these of two them large look with who That's trials. me patients. have pelvic remarkable forms Reproductive non XX for this three endpoints the take of treat for been treatment pain primary things well extension and care when at to XX% year, extremely elagolix other It's remarkable. out Number kind can but and elagolix resonate to these chronic that a see efficacy this such who surgeries, intervention non for what of have of dysmenorrhea endometriosis clinicians, you this or will menstrual maintenance
months described the used treatment, the long their has been the tool more change important how the twelve assess rates or much feel two responders improved of XX% range and to or improved. responses or who PGIC. XX% patients patient this in important After to as is As trials term these much responder very maybe impression from of global
year asked normal what that by are elagolix has is numbers out good used AbbVie with there add-back up density safety you is the and for about there women on are profile some that bone describe measurable for presentations mineral is or progressively bid judged talking is suggesting that more chronic in what’s slight widening range the if XXX confidence on drug for there follow data This the is a done Z-scores. remarkable baseline those really the around and very, quite a side, the their higher encouraging women’s all have with BMD will I the data endometriosis. So the there caused, of elagolix is are range Z-score dose. you to Z-scores women patients really question stopping that milligram high the suffering you the with towards that see very normal in a density for that this the more I robust and few their and whether in are patients about without reduction remarkable the that. up impact therapy very to response drug, period mineral intervals in with The – after bone see that not, in potential a speaks data was individuals. flip But the job their post-treatment to to interesting point were the return BMD look example at would as dose for in tends
is make some in data has other uterine fibroids I'd generated been the only comment remarkable studies. the Lastly
the been are on levels of quality trials activities, here health the cetera. conducted really a domains data with is has includes presented Phase including of impact replicate uterine menstrual sexual really with life for in you quality fibroids. expected not function, powerful of bleeding heavy et the This III top-line at The elagolix AbbVie women again, before data year. two areas this. programs of As this like suffering energy remarkable know self-consciousness, data And by on the impact related across some there of those end currently seen being life studies from all and at ASRM data
but of kind data the payers. just to to and is that not So also important patients, physicians
work. to a AbbVie our such at for So congrats outstanding colleagues
the programs that’s active forward in questions. that look the and with turn to to So clinic. currently I'll it an that five update on Kevin are back your
